Article Contents ::
- 1 Details About Generic Salt :: Methocar
- 2 Main Medicine Class:: Skeletal muscle relaxant,centrally acting
- 3 (meth-oh-CAR-buh-mahl) Robaxin, Robaxin Injectable, Robaxin-750 Class: Skeletal muscle relaxant/centrally acting
- 4 Drugs Class ::
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
Details About Generic Salt :: Methocar
Main Medicine Class:: Skeletal muscle relaxant,centrally acting
(meth-oh-CAR-buh-mahl)
Robaxin, Robaxin Injectable, Robaxin-750
Class: Skeletal muscle relaxant/centrally acting
Drugs Class ::
Action May cause relaxation of skeletal muscle via general CNS depression. Does not directly relax tense skeletal muscles.
Indications for Drugs ::
Indications Adjunctive therapy for relief of painful, acute musculoskeletal conditions; ontrol of neuromuscular manifestations of tetanus.
Drug Dose ::
Route/Dosage
Skeletal Muscle Relaxation
ADULTS: Initial dose: IV/IM 3 g over £ 3 consecutive days. Repeat course after 48 hr lapse if condition persists. PO 1.5 g qid. MAINTENANCE: PO 1 g qid or 750 mg q 4 hr, or 1.5 g tid. For first 48–72 hr, 6–8 g/day is recommended; then reduce to 4 g/day.
Tetanus
ADULTS: IV 1–2 g; additional 1–2 g may be added to infusion up to 3 g total. Repeat q 6 hr until oral form may be administered. CHILDREN: IV/IV infusion 15 mg/kg initially; then 15 mg/kg q 6 hr.
Contraindication ::
Contraindications Renal pathologic disorders (parenteral form).
Drug Precautions ::
Precautions
Pregnancy: Safety not established. Avoid use, if possible. Lactation: Undetermined. Children: Safety and efficacy in children < 12 yr not established, except for management of tetanus.
PATIENT CARE CONSIDERATIONS |
|
Drug Side Effects ::
Adverse Reactions
CV: Syncope; hypotension; bradycardia. CNS: Dizziness; lightheadedness; vertigo; headache; drowsiness; fainting; ild muscular incoordination; convulsions in epileptic patients. DERM: Urticaria; pruritus; rash; flushing. EENT: Blurred vision; conjunctivitis with nasal congestion; nystagmus; diplopia; etallic taste. GI: GI upset; nausea. OTHER: Thrombophlebitis; pain or sloughing at injection site; anaphylactic reaction; fever.
Drug Mode of Action ::
Action May cause relaxation of skeletal muscle via general CNS depression. Does not directly relax tense skeletal muscles.
Drug Interactions ::
Interactions None well documented.
Drug Assesment ::
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies. Note epilepsy and renal pathologic conditions.
- Perform physical assessment noting muscle tone, range of motion, pain, CNS function, mentation and vital signs.
- Observe IV site for phlebitis.
- Provide safe environment (eg, keep bed in low position with side rails up, instruct patient to call for assistance when rising).
- Move patient slowly from recumbent to sitting or standing position.
- Keep oxygen and epinephrine available in event of anaphylaxis.
- Monitor for effectiveness of drug and side effects, especially dizziness, drowsiness, rash, pruritus, fever and congestion.
- If patient experiences syncope, place in reverse Trendelenburg’s position and monitor vital signs.
- Notify physician if patient does not spontaneously recover.
- Notify physician if extravasation occurs.
|
Drug Storage/Management ::
Administration/Storage
- Administer parenteral form for no more than 3 days.
- Wait 48 hr before repeating with additional course if needed.
- For parenteral administration, do not administer SC; drug should be given IV or IM.
- Assess patency of IV site prior to administration; if patency is in doubt, start new IV to avoid extravasation.
- Administer via slow IV push or as infusion.
- Infuse in solution of D5W or saline solution £ 1 vial/250 ml.
- Keep prepared infusion at room temperature.
- For IV administration, place patient in recumbent position; ave patient remain recumbent for 10–15 min after administration to prevent orthostatic hypotension.
- Monitor vital signs and IV flow rate.
- For IM administration, inject deeply and do not exceed 5 ml in each gluteal area. Rotate injection sites.
- For oral administration, administer loading dose followed by maintenance dose.
- May crush tablets if necessary.
- Administer with food to decrease stomach upset.
- Store at room temperature.
Drug Notes ::
Patient/Family Education
- Instruct patient regarding additional therapy recommended to treat muscle spasm such as activity restrictions or physical therapy.
- Advise patient that drug may cause drowsiness, dizziness and lightheadedness and to use caution while driving or performing other tasks requiring mental alertness.
- Caution patient not to discontinue medication abruptly without consulting physician.
- Inform patient that urine may become different or darker color.
- Instruct patient to report these symptoms to physician: skin rash, itching, fever or nasal congestion.
- Caution patient to avoid sudden changes in position to prevent orthostatic hypotension.
- Instruct patient to avoid intake of alcoholic beverages or other CNS depressants.
- Advise patient not to take otc medications without consulting physician.